Is Conmed Corp (CNMD) a Bargain After 6.0% Drop? GF Value Says Undervalued
On October 06, 2026, Conmed Corp (CNMD) shares fell 6.0% to a current price of $44.48, marking a significant decline in the context of a 52-week range of $31.44
CNMD - CONMED Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$37.50
DETAILS
HIGH:
$39.00
LOW:
$36.00
MEDIAN:
$37.50
CONSENSUS:
$37.50
DOWNSIDE:
23.86%
Stock News
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
Canada Pension Plan Investment Board Buys Shares of 13,800 CONMED Corporation $CNMD
Canada Pension Plan Investment Board purchased a new position in CONMED Corporation (NYSE: CNMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,800 shares of the company's stock, valued at approximately $452,000. Other institutional investors also recently modified
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
CONMED Corporation: Organic Growth Is Masked By Divestitures
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
California State Teachers Retirement System Raises Stock Holdings in CONMED Corporation $CNMD
California State Teachers Retirement System lifted its stake in shares of CONMED Corporation (NYSE: CNMD) by 38.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,340 shares of the company's stock after acquiring an additional 10,845 shares during the
Arrowstreet Capital Limited Partnership Purchases 287,150 Shares of CONMED Corporation $CNMD
Arrowstreet Capital Limited Partnership lifted its position in shares of CONMED Corporation (NYSE: CNMD) by 217.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 419,092 shares of the company's stock after buying an additional 287,150 shares during the quarter. Arrowstreet Capital
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Q2 Earnings Call Highlights
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.15 per share a year ago.
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company's previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons.
CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.
Price Targets
Wells finds Conmed sale report 'little surprising' after refinance
$39.00
(was $41.98)
Wells Fargo
Conmed initiated with a Market Perform at BMO Capital
$36.00
(was $33.59)
BMO Capital
Conmed price target lowered to $61 from $91 at Needham
$61.00
(was $57.19)
Mike Matson
·
Needham
Needham Reiterates Buy Rating on CONMED (CNMD)
$97.00
(was $66.59)
Mike Matson
·
Needham
CONMED (CNMD) PT Lowered to $95 at Piper Sandler
$95.00
(was $64.34)
Matt O\'Brien
·
Piper Sandler
CONMED (CNMD) PT Lowered to $107 at Needham
$107.00
(was $70.01)
Mike Matson
·
Needham
Conmed price target lowered to $108 from $118 at Piper Sandler
$108.00
(was $83.39)
Matt O'Brien
·
Piper Sandler